VentvilВентвил
What is it?
A liver-derived polypeptide complex discussed alongside Livagen (KEDA) in experimental hepatology. The extract and tetrapeptide are separate preparations.
Research context
A liver-derived polypeptide complex discussed alongside Livagen (KEDA) in experimental hepatology. The extract and tetrapeptide are separate preparations.
- Working classification
- Tissue-derived polypeptide complex
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human trial established by linked review
- Study methods
- —Original reports separated from narrative reviews and patents
- Independent replication
- —Independent replication not established by this collection
- Source access
- —Linked abstracts, analytical papers, reviews and patents; individual scope shown below
- Safety evidence
- —Incomplete assessment; findings do not establish safety for personal use
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Where this preparation fits.
Liver: the molecular link
Ventvil → Livagen / KEDA
The 2020 Russian review discusses the liver complex and defined tetrapeptide together as separate experimental interventions.
Clinical boundary
The recovered review describes animal and cell models of fibrosis/hepatitis, not a human treatment trial.
Original model-specific papers and molecular characterization remain necessary. A shared research program is not proof of identical composition or effects.
Related preparations
The contextual sources below can concern a related extract, review or molecular link. They are not all direct studies of this profile’s compound.
Linked sources
Explore the research map and unresolved leads ↗
The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology
Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK · Adv Gerontol 33(1):159-164. PMID 32362099
Reviews liver polypeptide complex Ventvil and KEDA/Livagen in experimental fibrosis and hepatitis, with immune and antioxidant outcomes.
- Population / setting
- Animal and in-vitro liver pathology models
- What was checked
- Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Limitations & review scope
- Extract and tetrapeptide are separate interventions.
- This is a review of experimental models, not a clinical hepatitis treatment trial.
Source checked 2026-09-29. This is a source-linked record, not a completed evidence review.